ValiPharma
Therapeutics division with a promising cancer treatment in development.
Launch date
Market cap
€2.7m
Enterprise valuation
€3m (Public information from Sep 2024)
Share price
£0.01697 VAL.L
Company register number 05085935
Nuneaton England (HQ)
Financials
Estimates*
EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | - | - | - | <1m |
EBITDA | (<1m) | (<1m) | (3.2m) | (1.6m) | (1.7m) | (2.9m) | (2.5m) |
% EBITDA margin | - | - | - | - | - | - | (21295 %) |
Profit | - | - | (2.9m) | (1.7m) | (1.8m) | (2.8m) | (2.4m) |
% profit margin | - | - | - | - | - | - | (21226 %) |
R&D budget | - | - | 1.2m | <1m | <1m | <1m | <1m |
R&D % of revenue | - | - | - | - | - | - | 3993 % |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
N/A | Spinout | ||
N/A | Acquisition | ||
€290k | Grant | ||
Total Funding | €290k |
Recent News about ValiPharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.